Under construction – not a live service
Sign in
Not yet taking people in United StatesNo phase

Sensor Mat to Detect Body Position After Seizures in Epilepsy

Tests a sheet sensor that detects body position after seizures in adults with epilepsy.

Plain-language title generated from the registry record
Registry title: A Device to Prevent Sudden Unexpected Death in Epilepsy: Detecting Peri-Ictal Body Position

Key facts

Where
Boston, United StatesSee the site

Where in United States

  • Brigham and Women's HospitalBoston, United StatesNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Brigham and Women's Hospital
Trial code
NCT06135285
Record updated
27 July 2026
Original description
The goal of this study is to assess the performance of a commercial sheet sensor in determining body position after generalized tonic-clonic (GTC) seizures. If a sheet sensor could accurately detect GTC seizures, this could be a step towards autonomously repositioning patients with the aid of a smart mattress.Read full original descriptionShow less

A Device to Prevent Sudden Unexpected Death in Epilepsy: Detecting Peri-Ictal Body Position

The goal of this study is to assess the performance of a commercial sheet sensor in determining body position after generalized tonic-clonic (GTC) seizures. If a sheet sensor could accurately detect GTC seizures, this could be a step towards autonomously repositioning patients with the aid of a smart mattress.

Primary Objective

Milestones:

Feasibility objective: Monitor 50 patients with the objective of capturing at least 20 GTCS events. Primary analytic objective: Achieve detection of anatomical landmarks with body position change within 5 seconds with an accuracy of 75% both interictally and post-GTCS.

Secondary Objective Detect the postictal prone position with an accuracy of 100%.

Inclusion: Adults 18 years of age or older admitted to the BWH EMU with drug-resistant epilepsy, defined by the failure of at least two anti-seizure medications and a documented history of electroclinical seizures.

Exclusion: Patients admitted for medication adjustment only; Suspicion of functional dissociative seizures (psychogenic nonepileptic seizures).

ClinicalTrials.gov NCT06135285